TY - JOUR
T1 - Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism
AU - Martínez-Urbistondo, Diego
AU - de la Garza, Rocío G
AU - Villares-Fernández, Paula
AU - Font, Carme
AU - Schellong, Sebastian
AU - López-Núñez, Juan José
AU - Gil-Díaz, Aída
AU - Del Carmen Díaz-Pedroche, María
AU - Hirmerova, Jana
AU - Monreal, Manuel
AU - RIETE Investigators
A2 - Skride, Andris
N1 - Funding Information:
We express our gratitude to Sanofi Spain, LEO PHARMA and ROVI for supporting this Registry with an unrestricted educational grant. We also thank the RIETE Registry Coordinating Center, S&H Medical Science Service, for their quality control data, logistic and administrative support. MD Adarraga, J Aibar, J Alonso, C Amado, JI Arcelus, A Asuero, A Ballaz, R Barba, C Barbagelata, M Barrón, B Barrón-Andrés, A Blanco-Molina, F Beddar Chaib, E Botella, J Castro, L Chasco, J Criado, C de Ancos, J del Toro, P Demelo-Rodríguez, AM Díaz-Brasero, MC Díaz-Pedroche, JA Díaz-Peromingo, MV Di Campli, A Dubois-Silva, JC Escribano, F Espósito, AI Farfán-Sedano, C Fernández-Capitán, JL Fernández-Reyes, MA Fidalgo, K Flores, C Font, L Font, I Francisco, C Gabara, F Galeano-Valle, MA García, F García-Bragado, M García de Herreros, RG de la Garza, C García-Díaz, A Gil-Díaz, C Gómez-Cuervo, E Grau, L Guirado, J Gutiérrez, L Hernández-Blasco, L Jara-Palomares, MJ Jaras, D Jiménez, R Jiménez, C Jiménez-Alfaro, MD Joya, S Lainez-Justo, A Lalueza, A Latorre, J Lima, JL Lobo, L López-Jiménez, P López-Miguel, JJ López-Núñez, R López-Reyes, JB López-Sáez, A Lorenzo, O Madridano, A Maestre, PJ Marchena, M Martín del Pozo, F Martín-Martos, D Martínez-Urbistondo, C Mella, MI Mercado, J Moisés, M Monreal, A Muñoz-Blanco, JA Nieto, E Nofuentes-Pérez, MJ Núñez-Fernández, M Olid-Velilla, MC Olivares, J Osorio, S Otalora, R Otero, D Paredes, JM Pedrajas, JA Porras, J Portillo, I Redondo, C Rodríguez-Matute, V Rosa, P Ruiz-Artacho, J Ruiz-Ruiz, G Salgueiro, R Sánchez-Martínez, JF Sánchez-Muñoz-Torrero, T Sancho, S Soler, B Suárez-Rodríguez, JM Suriñach, MI Torres, A Torres-Sánchez, C Tolosa, J Trujillo-Santos, F Uresandi, B Valero, R Valle, JF Varona, L Vela, JR Vela, G Vidal, A Villalobos, P Villares, C Zamora, C Ay, S Nopp, I Pabinger, MM Engelen, T Vanassche , P Verhamme, J Hirmerova, R Malý, S Accassat, N Ait Abdallah, L Bertoletti, A Bura-Riviere, J Catella, F Couturaud, B Crichi, P Debourdeau, O Espitia, D Farge-Bancel, C Grange, H Helfer, K Lacut, R Le Mao, I Mahé , P Morange, F Moustafa, G Poenou, G Sarlon-Bartoli, P Suchon, I Quere, S Schellong, A Braester, B Brenner, G Kenet, I Tzoran, M Basaglia, F Bilora, C Bortoluzzi, B Brandolin, M Ciammaichella, A De Angelis, P Di Micco , E Imbalzano, S Merla, R Pesavento, P Prandoni, C Siniscalchi, A Tufano A, A Visonà, N Vo Hong, B Zalunardo , Y Nishimoto, Y Sato, K Make, A Skride, S Strautmane, S Fonseca, F Martins, J Meireles, M Bosevski, H Bounameaux, L Mazzolai, JA Caprini, HM Bui.
Publisher Copyright:
© 2021, Società Italiana di Medicina Interna (SIMI).
PY - 2022/4
Y1 - 2022/4
N2 - The association between elevated liver enzymes or FIB-4 (fibrosis index 4) and outcome in patients with venous thromboembolism (VTE) has not been evaluated. Data from patients in RIETE (Registro Informatizado Enfermedad TromboEmbólica) were used to assess the association between elevated liver enzymes or FIB-4 levels and the rates of major bleeding or death in apparent liver disease-free patients with acute VTE under anticoagulation therapy. A total of 6206 patients with acute VTE and without liver disease were included. Of them, 92 patients had major bleeding and 168 died under anticoagulation therapy. On multivariable analysis, patients with elevated liver enzymes were at increased mortality risk (HR: 1.58; 95% CI: 1.10-2.28), while those with FIB-4 levels > 2.67 points were at increased risk for major bleeding (HR: 1.69; 95% CI: 1.04-2.74). Evaluation of liver enzymes and FIB-4 index at baseline in liver disease-free patients with VTE may provide additional information on the risk for major bleeding or death during anticoagulation.
AB - The association between elevated liver enzymes or FIB-4 (fibrosis index 4) and outcome in patients with venous thromboembolism (VTE) has not been evaluated. Data from patients in RIETE (Registro Informatizado Enfermedad TromboEmbólica) were used to assess the association between elevated liver enzymes or FIB-4 levels and the rates of major bleeding or death in apparent liver disease-free patients with acute VTE under anticoagulation therapy. A total of 6206 patients with acute VTE and without liver disease were included. Of them, 92 patients had major bleeding and 168 died under anticoagulation therapy. On multivariable analysis, patients with elevated liver enzymes were at increased mortality risk (HR: 1.58; 95% CI: 1.10-2.28), while those with FIB-4 levels > 2.67 points were at increased risk for major bleeding (HR: 1.69; 95% CI: 1.04-2.74). Evaluation of liver enzymes and FIB-4 index at baseline in liver disease-free patients with VTE may provide additional information on the risk for major bleeding or death during anticoagulation.
UR - http://www.scopus.com/inward/record.url?scp=85116816148&partnerID=8YFLogxK
U2 - 10.1007/s11739-021-02858-x
DO - 10.1007/s11739-021-02858-x
M3 - Article
C2 - 34626318
SN - 1828-0447
VL - 17
SP - 725
EP - 734
JO - Internal and Emergency Medicine
JF - Internal and Emergency Medicine
IS - 3
ER -